息肉数量及结肠癌家族史与种系MYH突变的相关性。
Correlation of polyp number and family history of colon cancer with germline MYH mutations.
作者信息
Jo Won-Seok, Bandipalliam Prathap, Shannon Kristen M, Niendorf Kristin B, Chan-Smutko Gayun, Hur Chin, Syngal Sapna, Chung Daniel C
机构信息
Gastrointestinal Unit and Department of Medicine, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
出版信息
Clin Gastroenterol Hepatol. 2005 Oct;3(10):1022-8. doi: 10.1016/s1542-3565(05)00411-8.
BACKGROUND & AIMS: Affected individuals with biallelic MYH mutations are believed to display multiple adenomatous polyps without evidence of vertical transmission. Our goal was to determine the detection rate of germline MYH mutations in a high-risk gastrointestinal cancer clinic population by using polyp number as a selection criterion.
METHODS
Patients were screened for the 2 most common MYH mutations: Y165C and G382D. The complete MYH coding region was sequenced in cases with a heterozygous mutation.
RESULTS
Among 45 patients with more than 15 adenomatous polyps not diagnosed with familial adenomatous polyposis, 7 (15.6%) had biallelic MYH mutations. When 122 participants from a high-risk gastrointestinal cancer clinic who did not fulfill these criteria were tested, 2 additional patients with biallelic mutations were identified. Both had young-onset colorectal cancer (age, <50 y) with fewer than 15 polyps. Surprisingly, most of the 9 patients with biallelic MYH mutations reported family histories consistent with the hereditary nonpolyposis colorectal cancer syndrome (HNPCC), with 7 cases meeting at least 1 of the Bethesda criteria, 5 cases fulfilling 3 Bethesda criteria, and 2 cases fulfilling the Amsterdam II criteria.
CONCLUSIONS
Most individuals with MYH mutations exhibit multiple adenomatous polyps. However, 22% of cases were missed when this was the sole criterion for germline testing. A significant number reported a strong family history of cancer that was consistent with HNPCC. MYH testing thus can be considered for patients who meet clinical criteria for HNPCC in the absence of DNA mismatch repair gene mutations.
背景与目的
双等位基因MYH突变的患者被认为会出现多个腺瘤性息肉,且无垂直遗传证据。我们的目标是通过将息肉数量作为选择标准,确定高危胃肠道癌症门诊人群中种系MYH突变的检出率。
方法
对患者进行2种最常见的MYH突变筛查:Y165C和G382D。对杂合突变病例的MYH完整编码区进行测序。
结果
在45例未诊断为家族性腺瘤性息肉病且有超过15个腺瘤性息肉的患者中,7例(15.6%)有双等位基因MYH突变。对122名不符合这些标准的高危胃肠道癌症门诊参与者进行检测时,又发现了2例双等位基因突变患者。这两名患者均为青年起病的结直肠癌(年龄<50岁),息肉少于15个。令人惊讶的是,9例双等位基因MYH突变患者中,大多数报告的家族史与遗传性非息肉病性结直肠癌综合征(HNPCC)相符,7例至少符合一项贝塞斯达标准,5例符合三项贝塞斯达标准,2例符合阿姆斯特丹II标准。
结论
大多数MYH突变个体表现出多个腺瘤性息肉。然而,当这是种系检测的唯一标准时,22%的病例被漏诊。相当一部分患者报告有与HNPCC相符的强烈癌症家族史。因此,对于符合HNPCC临床标准但无DNA错配修复基因突变的患者,可考虑进行MYH检测。